HTT-1A Modulation via dsRNA Antisense Oligonucleotides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Huntington's disease (HD) fail to effectively counteract the neurodegenerative effects of the HTT-1A variant, which is a highly pathogenic fragment of the huntingtin protein associated with the progression of HD.
Innovation Solution
Development of double-stranded RNA (dsRNA) molecules comprising a sense strand and an antisense strand, where the antisense strand is substantially complementary to the HTT-1A nucleic acid sequence, designed to inhibit the expression of the HTT-1A gene by targeting specific sequences within the HTT-1A mRNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Huntington's disease are used, then general HD symptoms may be addressed, but the neurodegenerative effects of the HTT-1A variant are not effectively counteracted
Solution Approach 1:
The patent divides the HTT gene targeting approach into specific segments by designing antisense oligonucleotides that target only the HTT-1A variant transcript (comprising exon 1 and 5' part of intron 1) rather than the entire HTT gene. This segmentation allows selective inhibition of the pathogenic HTT-1A variant while preserving other HTT transcripts, thereby improving reliability against HTT-1A specifically without requiring broad adaptability to all HTT-related pathways.
Solution Approach 2:
The invention applies local quality by creating treatments with specific properties tailored to the HTT-1A variant's unique characteristics. The antisense oligonucleotides are designed with sequences that are substantially complementary to the specific nucleic acid sequence of HTT-1A, giving the treatment localized specificity to this pathogenic fragment rather than affecting the entire huntingtin protein or all HD symptoms uniformly.
2Reliability
If dsRNA molecules are designed to target specific HTT-1A mRNA sequences, then HTT-1A gene expression is effectively inhibited, but the complexity of the treatment increases
Solution Approach 1:
The patent extracts only the essential functional elements needed for HTT-1A inhibition by designing dsRNA molecules where the antisense strand is substantially complementary to specific HTT-1A mRNA sequences. This extraction approach focuses on the minimal required sequence complementarity to achieve reliable inhibition without incorporating unnecessary molecular complexity, thereby achieving effective HTT-1A suppression with optimized molecular design.
Solution Approach 2:
The invention utilizes parameter changes by optimizing the length and sequence composition of the antisense oligonucleotides to achieve effective HTT-1A binding. By adjusting parameters such as the degree of sequence complementarity, oligonucleotide length, and chemical modifications, the patent achieves reliable gene expression inhibition while managing molecular complexity through systematic parameter optimization rather than arbitrary structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA molecules effectively inhibit HTT-1A gene expression, reducing mRNA levels in brain regions affected by HD, thereby mitigating the neurodegenerative effects of the HTT-1A variant.
Implementation Method 1
the antisense strand comprises a sequence substantially complementary to a HTT nucleic acid sequence
Data Source
AI summary
This disclosure relates to novel HTT-1A targeting sequences. Novel HTT-1A targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.